Geneva, Switzerland & Barcelona, Spain – March 5, 2026 - ABCDx, a MedTech company developing rapid blood-based diagnostics for acute neurological conditions, today announced the grant of a key patent in China covering biomarker-based methods for stroke patient stratification and selection for reperfusion therapy.
The granted patent protects the use of specific blood biomarkers to identify patients with large vessel occlusion (LVO) and to support selection for thrombectomy, a time-critical intervention in acute ischemic stroke. China represents a strategically important market given the high incidence of stroke and the growing adoption of advanced reperfusion therapies.
This newly granted Chinese patent further strengthens ABCDx’s global intellectual property portfolio, which already includes granted patents in stroke and traumatic brain injury (TBI) across multiple jurisdictions. Together, these patents protect the company’s core approach of combining clinically validated biomarkers with rapid point-of-care technologies to enable earlier and more accurate decision-making in emergency settings.
“This patent grant in China is an important step for ABCDx,” said Jean-CharlesSanchez, CEO and Co-founder of ABCDx. “It reinforces the scientific and clinical foundation of our stroke programs and adds to our existing granted IP in stroke and TBI. Strong, well-aligned IP is critical as we move from platform development toward regulatory-grade products and international deployment.”
The patent originates from collaborative research conducted with leading academic and clinical partners and reflects ABCDx’s strategy to build defensible, clinically relevant IP around biomarker combinations with direct impact on patient management.
ABCDx continues to advance its pipeline of point-of-care diagnostic solutions for stroke, thrombosis, and brain injury, with ongoing regulatory, clinical, and industrialization activities in Europe, the United States, and selected international markets.
About ABCDx
ABCDx is a Swiss-Spanish diagnostics company developing blood-based tests for brain injury and acute neurological conditions. Its portfolio spans stroke, traumatic brain injury, and related indications, with a focus on rapid, objective, and clinically actionable biomarkers.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office OperationsSpecialist
